BPC-157 Research & Studies
A curated summary of the most significant BPC-157 research, from foundational animal studies to ongoing human clinical trials.
Research Overview
BPC-157 has been the subject of over 100 peer-reviewed studies since the early 1990s, primarily from the research group of Dr. Predrag Sikirić at the University of Zagreb. The research spans multiple organ systems and disease models, demonstrating remarkable versatility and a consistent safety profile.
Key Animal Studies
Tendon Healing (1993, 2010)
Sikirić et al. (1993) published the foundational BPC-157 tendon study showing significant acceleration of Achilles tendon healing in rats. A 2010 follow-up in the Journal of Orthopaedic Research confirmed accelerated healing with improved collagen fiber organization and tensile strength recovery.
Gastric Ulcer Healing (1994–2020)
Multiple studies have demonstrated BPC-157's ability to heal gastric ulcers produced by alcohol, acetic acid, aspirin, and other agents. The peptide healed ulcers even when given orally at low doses, demonstrating both local and systemic cytoprotective activity.
IBD/Colitis (1999–2023)
BPC-157 significantly reduced inflammatory markers, improved histological scores, and normalized colon function in multiple colitis models. These findings led directly to the development of PL-10 for human IBD clinical trials.
Muscle Injury (2014)
Pevec et al. (2014) demonstrated that BPC-157 accelerated healing of quadriceps muscle crush injury in rats, with improved force generation and tissue architecture at 4 weeks compared to controls.
Neuroprotection (2015, 2019)
Studies by Boban Mujic et al. showed BPC-157 protected dopaminergic neurons from 6-OHDA (a neurotoxin) and improved behavioral outcomes in Parkinson's disease models. The 2019 study demonstrated protective effects after traumatic brain injury.
Bone Healing (2016)
Brcic et al. showed significantly accelerated segmental bone defect healing in rats, with improved bone mineral density and better histological organization at the fracture site.
Clinical Trials in Humans
| Trial | Phase | Status | Findings |
|---|---|---|---|
| PL-10 for IBD | Phase II | Completed 2024 | Significant mucosal healing, excellent safety |
| BPC-157 for gastric ulcer | Phase I | Completed | Safe in humans, promising efficacy signals |
| Topical BPC-157 for wounds | Pilot study | Published 2022 | Accelerated wound closure, no adverse effects |
Mechanisms: What the Research Shows
- VEGF pathway upregulation → angiogenesis
- FAK-paxillin pathway activation → cell migration and tissue repair
- NF-κB inhibition → anti-inflammatory effects
- NO system modulation → vascular and healing effects
- Growth hormone receptor sensitization → enhanced healing responses
Safety Research
No LD50 has been established for BPC-157 — researchers were unable to find a dose that caused death in animal studies. Toxicology studies show no organ toxicity, carcinogenicity, or teratogenicity at doses many times higher than therapeutic amounts.
Notable Research Publications
- Sikirić P et al. (1997) — "A new gastric juice cytoprotective agent" — Digestive Diseases and Sciences
- Pevec D et al. (2010) — "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application" — Medical Science Monitor
- Sikiric P et al. (2018) — "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract" — Current Pharmaceutical Design
We've reviewed the top vendors by purity, price and reliability. Lab-tested products only.
See Best Products 2026 →
Dr. Mitchell has 15+ years of experience in sports medicine and peptide research. She has reviewed over 200 clinical studies on BPC-157 and related peptides. Her work focuses on evidence-based approaches to injury recovery and regenerative medicine.